Interventions aimed at disrupting leptin-EV pathways or modulating their downstream effects may offer novel strategies for potential therapeutic interventions for mitigating obesity-driven breast cancer aggressiveness. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.